Printer Friendly

MEDIMMUNE PRODUCT SALES CONTINUE TO GROW IN THIRD QUARTER

 GAITHERSBURG, Md., Nov. 9 /PRNewswire/ -- MedImmune, Inc. (NASDAQ-NMS: MEDI), today reported results for the third quarter ended Sept. 30, 1993. Sales of MedImmune's first product, CytoGam(R), increased to $2.3 million in the third quarter from none in the prior year period and from $1.9 million in the second quarter. CytoGam is a polyclonal antibody product used to prevent cytomegalovirus (CMV) disease in kidney transplant patients.
 "We are very pleased with the 26 percent increase in CytoGam sales over the second quarter," said Wayne T. Hockmeyer, Ph.D., Chairman and Chief Executive Officer. "We continue to be encouraged by our customers' response to both the benefits of the product and to the marketing program we initiated through our own sales force in January 1993."
 For the third quarter ended Sept. 30, 1993, MedImmune reported total revenues of $2.7 million and a net loss of $3.7 million or ($0.21) per share. Revenues and earnings for the prior year of $2.7 million and net loss of $0.9 million or ($0.05) per share reflected higher contract revenue from Merck & Co., Inc., for a collaborative HIV research program.
 Operating expenses for the 1993 third quarter were $6.7 million compared to $4.1 million in the 1992 quarter. This includes an increase of $1.2 million for cost of sales, which is the result of an increase in CytoGam shipments over the 1992 period. The increase in operating expenses also includes $1.2 million in marketing and selling expenses associated with CytoGam and preparations to launch RespiGam(TM) (formerly Respivir(TM)), if and when approved for marketing by the United States Food and Drug Administration (FDA). RespiGam, MedImmune's second product, is currently under review by the FDA for marketing approval for prevention of respiratory syncytial virus (RSV) infection in certain high risk children.
 "The results for the quarter and nine months were consistent with our expectations," said Wayne T. Hockmeyer, Ph.D., Chairman and Chief Executive Officer. "In addition, the completion of the private placement for $19.5 million, net proceeds, on Aug. 31, 1993 further strengthens our balance sheet to prepare us for future growth."
 MedImmune, Inc., was founded in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's corporate headquarters are in Gaithersburg.
 MEDIMMUNE, INC.
 Selected Financial Information
 (In thousands, except per share data)
 Condensed Statements of Operations (Unaudited)
 Period ended Three months Nine months
 Sept. 30, 1993 1992 1993 1992
 Revenues:
 Product sales $ 2,334 $ --- $ 5,740 $ 2,408
 Research and development 378 2,672 1,395 8,178
 Total 2,712 2,672 7,135 10,586
 Expenses:
 Cost of sales 1,308 138 3,226 2,361
 Research and development 3,133 3,090 9,061 8,257
 SG&A 2,273 915 6,697 2,421
 Total 6,714 4,143 18,984 13,039
 Interest income, net 396 595 1,305 1,868
 Loss before taxes (3,606) (876) (10,544) (585)
 Provision for income taxes 45 14 135 39
 Net loss (3,651) (890) (10,679) (624)
 Net loss per share (0.21) (0.05) (0.64) (0.04)
 Shares used in computing
 loss per share 17,154 16,638 16,777 16,753
 Condensed Balance Sheets
 9/30/93 12/31/92
 (Unaudited)
 Assets:
 Cash and marketable securities $ 46,238 $ 46,860
 Inventory 4,811 4,048
 Property and equipment, net 8,542 6,114
 Other assets 3,758 3,221
 Total $ 63,349 $ 60,243
 Liabilities and shareholders'
 equity:
 Accounts payable and accrued
 expenses $ 2,673 $ 1,513
 Obligations related to
 product acquisition 2,250 8,871
 Other liabilities 2,877 3,107
 Shareholders' equity 55,549 46,752
 Total $ 63,349 $ 60,243
 Common shares outstanding 14,590 13,386
 -0- 11/9/93
 /CONTACT: Emilio O. DiCataldo, senior vice president - finance and administration of MedImmune, 301-417-0770, or Anthony J. Russo, Ph.D., or Rhonda Chiger of Noonan/Russo Communications, Inc., 212-696-4455, ext. 207/
 (MEDI)


CO: MedImmune, Inc. ST: Maryland IN: MTC SU: ERN

WB-MP -- NY118 -- 2508 11/09/93 18:44 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 9, 1993
Words:690
Previous Article:ROCHESTER MEDICAL REPORTS FOURTH QUARTER PROFIT
Next Article:ARACRUZ CELULOSE REPORTS 1993 NINE MONTHS RESULTS IN U.S. GAAP
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters